Phase III Study of Sacituzumab Govitecan (IMMU-132) in Refractory/Relapsed Triple-Negative Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 21 Nov 2017
At a glance
- Drugs Sacituzumab govitecan (Primary) ; Capecitabine; Eribulin; Gemcitabine; Vinorelbine
- Indications Breast cancer; Male breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms ASCENT
- Sponsors Immunomedics
- 13 Nov 2017 According to an Immunomedics media release, abstract related to data from this trial were posted online and will be presented at the 2017 SABCS.
- 09 Nov 2017 According to an Immunomedics media release, first patient has been dosed in this trial.
- 18 Oct 2017 Status changed from not yet recruiting to recruiting.